克洛斯特里 (Clostridium butyricum) 以一种不依赖酸盐的方式降低肥胖
Jingyi Liao1,2, Yaoliang Liu1,2, Zhangming Pei1,2
1State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi 214122, China.
Microorganisms
|June 15, 2023
概括
(C. butyricum) 通过调节肠道微生物群和代谢物,表现出抗肥胖作用. 这项研究表明C.butyricum.
科学领域:
- 微生物学 微生物学
- 代谢性疾病研究研究.
- 肠道微生物组研究的研究
背景情况:
- 肠道微生物群越来越多地与肥胖有关.
- 黄菌 (C. butyricum) 是一种肠道共生生物,具有潜在的抗肥胖性质.
- 肥胖症中C.butyricum的精确机制尚未完全理解.
研究的目的:
- 在小鼠模型中研究C. butyricum分离物的抗肥胖作用.
- 探索C.butyricum对抗肥胖的生理功能和潜在机制.
主要方法:
- 在高脂肪饮食 (HFD) 的小鼠中给予五种C. butyricum分离物.
- 评估抗肥胖作用,包括脂肪形成,炎症,体重增加和代谢参数.
- 分析肠道的丁酸盐含量,酸和纯素代谢,以及肠道微生物群的组成.
主要成果:
- 所有C.butyricum分离物减少了皮下脂肪的形成和炎症.
- 两种有效的菌株显著降低了体重增加,脂质不良,肝硬化和炎症.
- 积极效应独立于增加的肠道丁酸盐或丁酸盐补充剂.
- 有效的菌株改变了酸和纯氨酸代谢,调节了肠道微生物群的组成.
结论:
- 在高脂肪饮食小鼠模型中,C.butyricum显示出显著的抗肥胖作用.
- 这些机制涉及控制肠道微生物组成和调节肠道代谢物,而不仅仅是酸盐.
- 这些发现支持C.butyricum作为肥胖和微生物制剂开发的潜在治疗剂.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
232
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
232
Obesity
549
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
549


